Laboratorios Farmacéuticos Rovi, S.A. (BME -Spanish Stock Exchanges and Markets: ROVI), a pan-European specialised company engaged in the research, development and marketing of biological specialties and a manufacturer with a high degree of technological differentiation, confirms that it has completed the manufacturing of the first batches of the COVID-19 Vaccine Moderna for European Union at its Madrid facilities.

After obtaining the conditional marketing authorisation (CMA) from the European Commission on 6 January, Moderna and ROVI have collaborated to maximise efficiency to make the COVID-19 Vaccine Moderna available to citizens in record time.

ROVI completed the installation of a new production line with equipment for formulation, aseptic filling, automatic visual inspection and labelling, in order to support the production of millions of doses of Moderna’s vaccine to supply markets outside the U.S.A. Furthermore, it has recruited additional personnel for the manufacturing and analysis operations.

Coinciding with the arrival of the first batches in European countries, including Spain, ROVI’s management highlights the work of its team over recent months, which has made the increase in the manufacturing capacity possible, as well as the production of the first vials that are now reaching the European markets in record time and will help to immunise the population.

“We are very satisfied with ROVI’s contribution, which will make it part of the solution, in record time, to this pandemic that is affecting all of us, and we will continue to support Moderna in the continued supply of its vaccine”, they  explain.

The European Commission granted a conditional marketing authorisation (CMA) for the COVID-19 Vaccine Moderna on 6 January 2021, based on the recommendation of the European Medicines Agency (EMA) for its use for active immunisation to prevent COVID-19 caused by the SARS-CoV-2 virus in persons aged 18 or over. To date, the distribution of the COVID-19 Vaccine Moderna has likewise been authorised in the United States, Canada, Israel and the United Kingdom. Iceland, Norway and Switzerland have also granted marketing authorisations broader support to Moderna in their large-scale distribution. We expect this increased collaboration with Moderna to help us become their long-term manufacturing partner. I would also like to thank the Ministry of Health and the Spanish Medicines Agency for making themselves available to us and providing their support during this entire process. This has been of vital importance”.